---
document_datetime: 2025-04-09 11:23:44
document_pages: 12
document_pathfilename: www.ema.europa.eu/en/documents/procedural-steps-after/quinsair-epar-procedural-steps-taken-scientific-information-after-authorisation_en.pdf
document_name: quinsair-epar-procedural-steps-taken-scientific-information-after-authorisation_en.pdf
version: success
processing_time: 6.3380404
conversion_datetime: 2025-12-28 00:33:58.717324
docling_version:
  docling-serve: 1.9.0
  docling-jobkit: 1.8.0
  docling: 2.66.0
  docling-core: 2.57.0
  docling-ibm-models: 3.10.3
  docling-parse: 4.7.2
  python: cpython-313 (3.13.11)
  plaform: macOS-26.2-arm64-arm-64bit-Mach-O
---
## Quinsair

Procedural steps taken and scientific information after the authorisation

| Application number   | Scope                                                                                          | Opinion/ Notification 1 issued on   | Commission Decision Issued 2 / amended on   | Product Information affected 3   | Summary                                                                                                                                                                                                                                                                                                                                                              |
|----------------------|------------------------------------------------------------------------------------------------|-------------------------------------|---------------------------------------------|----------------------------------|----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|
| IB/0039              | C.I.z - Changes (Safety/Efficacy) of Human and Veterinary Medicinal Products - Other variation | 01/04/2025                          |                                             | SmPC, Labelling and PL           | To update the existing information under the Description of selected adverse drug reactions in section 4.8 of the SmPC, adding new aspects of prolonged, disabling and potentially irreversible adverse drug reactions and reference to section 4.4. The Package leaflet is updated accordingly (section 4). The Applicant take this opportunity to apply some Minor |

<!-- image -->

<!-- image -->

<div style=\"page-break-after: always\"></div>

|         |                                                                                                                                                                                                                                              |            |            |                       | corrections to Slovenia, Czech R., Spain, Portugal, Greece and Latvia translations.                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                            |
|---------|----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|------------|------------|-----------------------|--------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|
| SW/0038 | Post Authorisation Safety Study results - EMEA/H/C/PSR/S/0046 - Variation                                                                                                                                                                    | 30/05/2024 | 26/07/2024 | SmPC, Annex II and PL | In view of the available data from the PASS final study report, the PRAC considers that changes to the product information and the conditions of the marketing authorisation are warranted. This study is a condition of the authorisation and Annex II should therefore be updated, as the study has been completed. The information about additional monitoring, including the black triangle, should also be removed. The footnote in section 4.8 of the SmPC referencing the statement 'adverse events with uncertain relatedness to Quinsair but which are known to be associated with systemic administration of levofloxacin and/or are plausibly associated with Quinsair and were reported more frequently than with placebo in clinical studies' is no longer considered applicable for haemoptysis. Therefore, the asterisk next to haemoptysis referring to this statement should be deleted. In addition, the RMP has been updated to reflect the PRAC conclusions and version 3.2 of the Quinsair RMP is agreed. |
| IA/0037 | A.4 - Administrative change - Change in the name and/or address of a manufacturer or an ASMF holder or supplier of the AS, starting material, reagent or intermediate used in the manufacture of the AS or manufacturer of a novel excipient | 29/02/2024 | n/a        |                       |                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                |
| IA/0036 | A.5.b - Administrative change - Change in the name and/or address of a manufacturer/importer of the finished product, including quality control sites (excluding manufacturer for batch release)                                             | 27/11/2023 | n/a        |                       |                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                |

<div style=\"page-break-after: always\"></div>

| PSUSA/10429 /202205   | Periodic Safety Update EU Single assessment - levofloxacin (Inhalation use)                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                     | 12/01/2023   | n/a        |          | PRAC Recommendation - maintenance   |
|-----------------------|-----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|--------------|------------|----------|-------------------------------------|
| IB/0035               | B.II.b.5.z - Change to in-process tests or limits applied during the manufacture of the finished product - Other variation                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                      | 23/11/2022   | n/a        |          |                                     |
| IB/0034               | C.I.11.z - Introduction of, or change(s) to, the obligations and conditions of a marketing authorisation, including the RMP - Other variation                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                   | 23/11/2022   | 19/10/2023 | Annex II |                                     |
| IB/0032/G             | This was an application for a group of variations. B.I.b.1.c - Change in the specification parameters and/or limits of an AS, starting material/intermediate/reagent - Addition of a new specification parameter to the specification with its corresponding test method B.I.b.1.b - Change in the specification parameters and/or limits of an AS, starting material/intermediate/reagent - Tightening of specification limits B.I.b.1.z - Change in the specification parameters and/or limits of an AS, starting material/intermediate/reagent - Other variation B.I.b.1.z - Change in the specification parameters and/or limits of an AS, starting material/intermediate/reagent - Other variation B.I.b.2.z - Change in test procedure for AS or starting material/reagent/intermediate - Other variation | 03/05/2022   | n/a        |          |                                     |

<div style=\"page-break-after: always\"></div>

|         | B.I.b.2.a - Change in test procedure for AS or starting material/reagent/intermediate - Minor changes to an approved test procedure B.I.b.2.e - Change in test procedure for AS or starting material/reagent/intermediate - Other changes to a test procedure (including replacement or addition) for the AS or a starting material/intermediate A.7 - Administrative change - Deletion of manufacturing sites A.4 - Administrative change - Change in the name and/or address of a manufacturer or an ASMF holder or supplier of the AS, starting material, reagent or intermediate used in the manufacture of the AS or manufacturer of a novel excipient A.4 - Administrative change - Change in the name and/or address of a manufacturer or an ASMF holder or supplier of the AS, starting material, reagent or intermediate used in the manufacture of the AS or   |            |            |             |
|---------|--------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|------------|------------|-------------|
| IB/0030 | C.I.11.z - Introduction of, or change(s) to, the obligations and conditions of a marketing authorisation, including the RMP - Other variation                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                            | 05/01/2022 | 08/07/2022 | Annex II    |
| IA/0031 | A.5.b - Administrative change - Change in the name and/or address of a manufacturer/importer of the finished product, including quality control sites (excluding manufacturer for batch release)                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                         | 29/10/2021 | n/a        |             |
| IB/0029 | C.I.z - Changes (Safety/Efficacy) of Human and Veterinary Medicinal Products - Other variation                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                           | 06/08/2021 | 08/07/2022 | SmPC and PL |

<div style=\"page-break-after: always\"></div>

<!-- image -->

| IB/0027/G   | This was an application for a group of variations.   | 13/01/2021   | n/a   |
|-------------|------------------------------------------------------|--------------|-------|

<div style=\"page-break-after: always\"></div>

| corresponding test B.I.b.2.c - Change starting material/reagent/intermediate changes to a test does not have a significant quality of the AS B.I.b.2.a - Change starting material/reagent/intermediate changes to an approved B.I.b.2.a - Change starting material/reagent/intermediate changes to an approved B.I.b.2.a - Change starting material/reagent/intermediate changes to an approved B.I.b.2.a - Change starting material/reagent/intermediate changes to an approved B.I.b.2.a - Change starting material/reagent/intermediate changes to an approved B.I.b.2.a - Change starting material/reagent/intermediate changes to an approved B.I.b.2.a - Change starting material/reagent/intermediate changes to an approved B.I.b.2.a - Change starting material/reagent/intermediate changes to an approved B.I.b.2.a - Change   |
|-------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|

<div style=\"page-break-after: always\"></div>

<!-- image -->

|         | changes to an approved test procedure B.I.b.1.d - Change in the specification parameters and/or limits of an AS, starting material/intermediate/reagent - Deletion of a non- significant specification parameter (e.g. deletion of an obsolete parameter) B.I.b.1.c - Change in the specification parameters and/or limits of an AS, starting material/intermediate/reagent - Addition of a new specification parameter to the specification with its corresponding test method B.I.b.1.c - Change in the specification parameters and/or limits of an AS, starting material/intermediate/reagent - Addition of a new specification parameter to the specification with its corresponding test method B.I.b.1.c - Change in the specification parameters and/or limits of an AS, starting material/intermediate/reagent - Addition of a new specification parameter to the specification with its corresponding test method B.I.b.1.b - Change in the specification parameters and/or limits of an AS, starting material/intermediate/reagent - Tightening of specification limits B.I.a.2.e - Changes in the manufacturing process of the AS - Minor change to the restricted part of an   |            |     |
|---------|---------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|------------|-----|
| IA/0028 | B.II.b.3.a - Change in the manufacturing process of the finished or intermediate product - Minor change in the manufacturing process                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                        | 07/01/2021 | n/a |

<div style=\"page-break-after: always\"></div>

| IAIN/0026           | C.I.z - Changes (Safety/Efficacy) of Human and Veterinary Medicinal Products - Other variation                                                                                                                                                                                                                                                                                                                                                                                               | 12/11/2020   | 21/05/2021   | SmPC and PL                      |                                   |
|---------------------|----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|--------------|--------------|----------------------------------|-----------------------------------|
| IB/0025/G           | This was an application for a group of variations. B.II.b.3.a - Change in the manufacturing process of the finished or intermediate product - Minor change in the manufacturing process B.II.b.5.b - Change to in-process tests or limits applied during the manufacture of the finished product - Addition of a new test(s) and limits B.II.e.5.a.2 - Change in pack size of the finished product - Change in the number of units (e.g. tablets, ampoules, etc.) in a pack - Change outside | 29/05/2020   | 21/05/2021   | SmPC, Labelling and PL           |                                   |
| IA/0024             | A.7 - Administrative change - Deletion of manufacturing sites                                                                                                                                                                                                                                                                                                                                                                                                                                | 23/03/2020   | n/a          |                                  |                                   |
| R/0022              | Renewal of the marketing authorisation.                                                                                                                                                                                                                                                                                                                                                                                                                                                      | 12/12/2019   | 13/02/2020   | SmPC, Annex II, Labelling and PL |                                   |
| PSUSA/10429 /201905 | Periodic Safety Update EU Single assessment - levofloxacin (Inhalation use)                                                                                                                                                                                                                                                                                                                                                                                                                  | 16/01/2020   | n/a          |                                  | PRAC Recommendation - maintenance |
| IAIN/0021/G         | This was an application for a group of variations. A.7 - Administrative change - Deletion of manufacturing sites B.I.b.1.d - Change in the specification parameters                                                                                                                                                                                                                                                                                                                          | 06/06/2019   | n/a          |                                  |                                   |

<div style=\"page-break-after: always\"></div>

|          | and/or limits of an AS, starting material/intermediate/reagent - Deletion of a non- significant specification parameter (e.g. deletion of an obsolete parameter) B.II.b.2.c.1 - Change to importer, batch release arrangements and quality control testing of the FP - Replacement or addition of a manufacturer responsible for importation and/or batch release - Not including batch control/testing B.III.2.b - Change to comply with Ph. Eur. or with a national pharmacopoeia of a Member State - Change to comply with an update of the relevant monograph of the Ph. Eur. or national pharmacopoeia of a Member State                                            |            |            |                  |                                                                                |
|----------|--------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|------------|------------|------------------|--------------------------------------------------------------------------------|
| N/0020   | Minor change in labelling or package leaflet not connected with the SPC (Art. 61.3 Notification)                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                         | 22/02/2019 | 13/02/2020 | Labelling and PL |                                                                                |
| A31/0010 | Pursuant to Article 31 of Directive 2001/83/EC, the German National Competent Authority on 1 February 2017 triggered a referral resulting from pharmacovigilance data, and requested the PRAC to review and assess the risk of long-lasting, disabling, and potentially permanent serious adverse drug reactions associated with the use of (luoro)quinolones. Furthermore, the PRAC was requested to assess the impact of this safety concern on the overall benefit- risk balance of quinolones and fluoroquinolones for systemic and inhalation use and the need for adequate risk minimisation measures and issue a recommendation on whether the products should be | 15/11/2018 | 14/02/2019 | SmPC and PL      | Please refer to the assessment report: Quinsair EMEA/H/A-31/1452/C/002789/0010 |

<div style=\"page-break-after: always\"></div>

|                     | maintained, varied, suspended or revoked. As the request resulted from the evaluation of data resulting from pharmacovigilance activities, the PRAC issued a recommendation to the Committee for Medicinal Products for Human Use (CHMP).   |            |            |                        |
|---------------------|---------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|------------|------------|------------------------|
| PSUSA/10429 /201805 | Periodic Safety Update EU Single assessment - levofloxacin (Inhalation use)                                                                                                                                                                 | 17/01/2019 | n/a        |                        |
| IAIN/0019           | B.II.b.1.a - Replacement or addition of a manufacturing site for the FP - Secondary packaging site                                                                                                                                          | 13/11/2018 | n/a        |                        |
| IAIN/0018           | C.I.z - Changes (Safety/Efficacy) of Human and Veterinary Medicinal Products - Other variation                                                                                                                                              | 24/10/2018 | 14/02/2019 | SmPC and PL            |
| T/0016              | Transfer of Marketing Authorisation                                                                                                                                                                                                         | 18/05/2018 | 07/06/2018 | SmPC, Labelling and PL |
| PSUSA/10429 /201705 | Periodic Safety Update EU Single assessment - levofloxacin (Inhalation use)                                                                                                                                                                 | 11/01/2018 | n/a        |                        |
| IAIN/0015           | A.1 - Administrative change - Change in the name and/or address of the MAH                                                                                                                                                                  | 09/01/2018 | 07/06/2018 | SmPC, Labelling and PL |
| IAIN/0013           | A.1 - Administrative change - Change in the name and/or address of the MAH                                                                                                                                                                  | 29/08/2017 | 07/06/2018 | SmPC, Labelling and PL |

<div style=\"page-break-after: always\"></div>

| PSUSA/10429 /201611   | Periodic Safety Update EU Single assessment - levofloxacin (Inhalation use)                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                            | 09/06/2017   | n/a        |                        | PRAC Recommendation - maintenance   |
|-----------------------|----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|--------------|------------|------------------------|-------------------------------------|
| IA/0011/G             | This was an application for a group of variations. A.4 - Administrative change - Change in the name and/or address of a manufacturer or an ASMF holder or supplier of the AS, starting material, reagent or intermediate used in the manufacture of the AS or manufacturer of a novel excipient A.5.b - Administrative change - Change in the name and/or address of a manufacturer/importer of the finished product, including quality control sites (excluding manufacturer for batch release) B.II.b.3.a - Change in the manufacturing process of the finished or intermediate product - Minor change in the manufacturing process B.II.b.5.c - Change to in-process tests or limits applied during the manufacture of the finished | 07/04/2017   | n/a        |                        |                                     |
| PSUSA/10429 /201605   | Periodic Safety Update EU Single assessment - levofloxacin (Inhalation use)                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                            | 12/01/2017   | n/a        |                        | PRAC Recommendation - maintenance   |
| IAIN/0008             | A.1 - Administrative change - Change in the name and/or address of the MAH                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                             | 16/12/2016   | 16/02/2017 | SmPC, Labelling and PL |                                     |
| PSUSA/10429 /201509   | Periodic Safety Update EU Single assessment - levofloxacin (Inhalation use)                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                            | 13/05/2016   | n/a        |                        | PRAC Recommendation - maintenance   |
| IAIN/0006/G           | This was an application for a group of variations.                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                     | 29/02/2016   | 16/02/2017 | Annex II and           |                                     |

<div style=\"page-break-after: always\"></div>

|         | B.II.b.1.a - Replacement or addition of a manufacturing site for the FP - Secondary packaging site B.II.b.2.c.2 - Change to importer, batch release arrangements and quality control testing of the FP - Including batch control/testing   |            |            | PL                     |
|---------|--------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|------------|------------|------------------------|
| T/0002  | Marketing Authorisation Transfer from Regintel Ltd to Raptor Pharmaceuticals Europe B.V. Transfer of Marketing Authorisation                                                                                                               | 16/11/2015 | 27/11/2015 | SmPC, Labelling and PL |
| IB/0003 | C.I.z - Changes (Safety/Efficacy) of Human and Veterinary Medicinal Products - Other variation                                                                                                                                             | 12/11/2015 | n/a        |                        |
| T/0001  | Marketing Authorisation Transfer from Aptalis Pharma SAS to Regintel Limited. Transfer of Marketing Authorisation                                                                                                                          | 26/08/2015 | 14/09/2015 | SmPC, Labelling and PL |